A new era of improving progression-free survival with dual blockade in postmenopausal HR+, HER2- advanced breast cancer

Cancer Treatment Reviews

Volumn 41, Issue 2, 2015, Pages 94-104

  Jerusalem, Guy ^a   Bachelot, Thomas ^b   Barrios, Carlos ^c   Neven, Patrick ^d   Di Leo, Angelo ^e   Janni, Wolfgang ^f   de Boer, Richard ^g  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b CENTRE LÉON BÉRARD   (France)

^c PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^e HOSPITAL OF PRATO   (Italy)

^f UNIVERSITY OF ULM   (Germany)

^g ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

Endocrine therapy; Everolimus; Hormone receptor positive advanced breast cancer; MTOR inhibitor; Overall survival; Progression free survival

Indexed keywords

ANASTROZOLE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EVEROLIMUS; EXEMESTANE; FULVESTRANT; LETROZOLE; TAMOXIFEN; TEMSIROLIMUS; ANDROSTANE DERIVATIVE; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; AROMATASE INHIBITOR; ERBB2 PROTEIN, HUMAN; ESTRADIOL; ESTROGEN RECEPTOR; MONOCLONAL ANTIBODY; NITRILE; PROGESTERONE RECEPTOR; RAPAMYCIN; TRIAZOLE DERIVATIVE; TUMOR MARKER;

BREAST CANCER; CANCER GROWTH; CANCER HORMONE THERAPY; FEMALE; HUMAN; INTRACELLULAR SIGNALING; MOLECULARLY TARGETED THERAPY; OVERALL SURVIVAL; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTMENOPAUSE; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; REVIEW; TIME TO TREATMENT; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; CHEMISTRY; CLINICAL TRIAL (TOPIC); DISEASE FREE SURVIVAL; MORTALITY; PROCEDURES; TREATMENT FAILURE; TREATMENT OUTCOME;

ANDROSTADIENES; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AROMATASE INHIBITORS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; DISEASE-FREE SURVIVAL; ESTRADIOL; FEMALE; HUMANS; MOLECULAR TARGETED THERAPY; NITRILES; PATIENT SELECTION; POSTMENOPAUSE; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SIROLIMUS; TREATMENT FAILURE; TREATMENT OUTCOME; TRIAZOLES; TUMOR MARKERS, BIOLOGICAL;

EID: 84921724894     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2014.12.011     Document Type: Review

References (64)

1. Zardavas D., Baselga J., Piccart M. Emerging targeted agents in metastatic breast cancer. Nat Rev Clin Oncol 2013, 10(4):191-210. 10.1038/nrclinonc.2013.29.
2. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998, 351(9114):1451-1467.
3. Partridge A.H., Rumble R.B., Carey L.A., Come S.E., Davidson N.E., Di Leo A., et al. Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2014, 32(29):3307-3329. 10.1200/JCO.2014.56.7479.
4. Cardoso F., Costa A., Norton L., Senkus E., Aapro M., Andre F., et al. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). Ann Oncol 2014, 25(10):1871-1888. 10.1093/annonc/mdu385.
5. Ring A., Dowsett M. Mechanisms of tamoxifen resistance. Endocr Relat Cancer 2004, 11(4):643-658. 10.1677/erc.1.00776.
6. Cardoso F., Costa A., Norton L., Cameron D., Cufer T., Fallowfield L., et al. 1st International consensus guidelines for advanced breast cancer (ABC 1). Breast 2012, 21(3):242-252. 10.1016/j.breast.2012.03.003.
7. Gradishar W.J., Anderson B.O., Blair S.L., Burstein H.J., Cyr A., Elias A.D., et al. Breast cancer version 3.2014. J Natl Compr Canc Netw 2014, 12(4):542-590.
8. Miller T.W., Balko J.M., Arteaga C.L. Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer. J Clin Oncol 2011, 29(33):4452-4461. 10.1200/JCO.2010.34.4879.
9. Shim W.S., Conaway M., Masamura S., Yue W., Wang J.P., Kmar R., et al. Estradiol hypersensitivity and mitogen-activated protein kinase expression in long-term estrogen deprived human breast cancer cells in vivo. Endocrinology 2000, 141(1):396-405. 10.1210/endo.141.1.7270.
10. Stephen R.L., Shaw L.E., Larsen C., Corcoran D., Darbre P.D. Insulin-like growth factor receptor levels are regulated by cell density and by long term estrogen deprivation in MCF7 human breast cancer cells. J Biol Chem 2001, 276(43):40080-40086. 10.1074/jbc.M105892200.
11. Campbell R.A., Bhat-Nakshatri P., Patel N.M., Constantinidou D., Ali S., Nakshatri H. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. J Biol Chem 2001, 276(13):9817-9824. 10.1074/jbc.M010840200.
12. Shaw R.J., Cantley L.C. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 2006, 441(7092):424-430. 10.1038/nature04869.
13. Zardavas D., Fumagalli D., Loi S. Phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway inhibition: a breakthrough in the management of luminal (ER+/HER2-) breast cancers?. Curr Opin Oncol 2012, 24(6):623-634. 10.1097/CCO.0b013e328358a2b5.
14. de Graffenried L.A., Friedrichs W.E., Russell D.H., Donzis E.J., Middleton A.K., Silva J.M., et al. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt activity. Clin Cancer Res 2004, 10(23):8059-8067. 10.1158/1078-0432.CCR-04-0035.
15. Boulay A., Rudloff J., Ye J., Zumstein-Mecker S., O'Reilly T., Evans D.B., et al. Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer. Clin Cancer Res 2005, 11(14):5319-5328. 10.1158/1078-0432.CCR-04-2402.
16. Mehta R.S., Barlow W.E., Albain K.S., Vandenberg T.A., Dakhil S.R., Tirumali N.R., et al. Combination anastrozole and fulvestrant in metastatic breast cancer. N Engl J Med 2012, 367(5):435-444. 10.1056/NEJMoa1201622.
17. Bergh J., Jonsson P.E., Lidbrink E.K., Trudeau M., Eiermann W., Brattstrom D., et al. FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer. J Clin Oncol 2012, 30(16):1919-1925. 10.1200/JCO.2011.38.1095.
18. Johnston S.R., Kilburn L.S., Ellis P., Dodwell D., Cameron D., Hayward L., et al. Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial. Lancet Oncol 2013, 14(10):989-998. 10.1016/S1470-2045(13)70322-X.
19. Loibl S., De La Haba J.R., Von Minckwitz G., Morales S., Crespo C., Anton A., et al. Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer - final analysis LEA study. Eur J Cancer 2013, 49:S399.
20. Wolff A.C., Lazar A.A., Bondarenko I., Garin A.M., Brincat S., Chow L., et al. Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer. J Clin Oncol 2013, 31(2):195-202. 10.1200/JCO.2011.38.3331.
21. Yardley D.A., Noguchi S., Pritchard K.I., Burris H.A., Baselga J., Gnant M., et al. Everolimus plus exemestane in postmenopausal patients with HR+ breast cancer: BOLERO-2 final progression-free survival analysis. Adv Ther 2013, 30(10):870-884. 10.1007/s12325-013-0060-1.
22. Chia S., Gradishar W., Mauriac L., Bines J., Amant F., Federico M., et al. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol 2008, 26(10):1664-1670. 10.1200/JCO.2007.13.5822.
23. Martin M., Loibl S., Von Minckwitz G., Morales S., Crespo C., Anton A., et al. Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer-first efficacy results from the LEA study. Cancer Res 2012, 72(24). [abstract S1-7].
24. Baselga J., Campone M., Piccart M., Burris H.A., Rugo H.S., Sahmoud T., et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012, 366(6):520-529. 10.1056/NEJMoa1109653.
25. Buckner J.C., Forouzesh B., Erlichman C., Hidalgo M., Boni J.P., Dukart G., et al. Phase I, pharmacokinetic study of temsirolimus administered orally to patients with advanced cancer. Invest New Drugs 2010, 28(3):334-342. 10.1007/s10637-009-9257-1.
26. Beck J.T., Hortobagyi G.N., Campone M., Lebrun F., Deleu I., Rugo H.S., et al. Everolimus plus exemestane as first-line therapy in HR(+), HER2(-) advanced breast cancer in BOLERO-2. Breast Cancer Res Treat 2014, 143(3):459-467. 10.1007/s10549-013-2814-5.
27. Hortobagyi G.N., Piccart-Gebhart M.J., Rugo H.S., Burris H.A., Campone M., Noguchi S., et al. Correlation of molecular alterations with efficacy of everolimus in hormone receptor-positive, HER2-negative advanced breast cancer: results from BOLERO-2. J Clin Oncol 2013, 31(Suppl.). [abstract LBA509].
28. Rugo H.S., Pritchard K.I., Gnant M., Noguchi S., Piccart M., Hortobagyi G., et al. Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2. Ann Oncol 2014, 25(4):808-815. 10.1093/annonc/mdu009.
29. Piccart M., Hortobagyi G.N., Campone M., Pritchard K.I., Lebrun F., Ito Y., et al. Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2. Ann Oncol 2014, 25(12):2357-2362. 10.1093/annonc/mdu456.
30. Campone M., Beck J.T., Gnant M., Neven P., Pritchard K.I., Bachelot T., et al. Health-related quality of life and disease symptoms in postmenopausal women with HR(+), HER2(-) advanced breast cancer treated with everolimus plus exemestane versus exemestane monotherapy. Curr Med Res Opin 2013, 29(11):1463-1473. 10.1185/03007995.2013.836078.
31. Afinitor [package insert] 2014, Novartis Pharmaceuticals Corporation, East Hanover, NJ, http://www.pharma.us.novartis.com/product/pi/pdf/afinitor.pdf [accessed 14.10.14].
32. Afinitor 2.5mg tablets [summary of product characteristics] 2013, Novartis Pharma GmbH, Nuremberg, Germany, http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001038/WC500022814.pdf [accessed 14.10.14].
33. Tabernero J., Rojo F., Calvo E., Burris H., Judson I., Hazell K., et al. Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol 2008, 26(10):1603-1610. 10.1200/JCO.2007.14.5482.
34. Sabatini D.M. mTOR and cancer: insights into a complex relationship. Nat Rev Cancer 2006, 6(9):729-734. 10.1038/nrc1974.
35. O'Reilly K.E., Rojo F., She Q.B., Solit D., Mills G.B., Smith D., et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006, 66(3):1500-1508. 10.1158/0008-5472.CAN-05-2925.
36. Sun S.Y., Rosenberg L.M., Wang X., Zhou Z., Yue P., Fu H., et al. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res 2005, 65(16):7052-7058. 10.1158/0008-5472.CAN-05-0917.
37. Sarbassov D.D., Guertin D.A., Ali S.M., Sabatini D.M. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005, 307(5712):1098-1101. 10.1126/science.1106148.
38. Jacinto E., Loewith R., Schmidt A., Lin S., Ruegg M.A., Hall A., et al. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol 2004, 6(11):1122-1128. 10.1038/ncb1183.
39. ClinicalTrials.gov. Phase III study of BKM120/placebo with fulvestrant in postmenopausal patients with hormone receptor positive HER2-negative locally advanced or metastatic breast cancer refractory to aromatase inhibitor (BELLE-2). [accessed 14.10.14]. http://www.clinicaltrials.gov/ct2/show/NCT01610284?term=BELLE-2%26rank=1.
40. Iwata H., Baselga J., Campone M., Arteaga C.L., Cortes J., Jonat W., et al. Ph III randomized studies of the oral pan-PI3K inhibitor buparlisib (BKM120) with fulvestrant in postmenopausal women with HR+/HER2- locally advanced or metastatic breast cancer (BC) after aromatase inhibitor (AI; BELLE-2) or AI and mTOR inhibitor (BELLE-3) treatment. Poster presented at 2013 ASCO Annual Meeting; May 31-June 4, Chicago, IL 2013, [abstract TPS650].
41. ClinicalTrials.gov. A phase III study of BKM120 with fulvestrant in patients with HR+, HER2-, AI treated, locally advanced or metastatic breast cancer who progressed on or after mTORi (BELLE-3). [accessed 14.10.14]. http://www.clinicaltrials.gov/ct2/show/NCT01633060?term=BELLE-3%26rank=1.
42. ClinicalTrials.gov. A study of palbociclib (PD-0332991) + letrozole vs. letrozole for 1st line treatment of postmenopausal women with ER+/HER2- advanced breast cancer (PALOMA-2). [accessed 14.10.14]. http://www.clinicaltrials.gov/ct2/show/NCT01740427?term=palbociclib+breast+cancer%26rank=2%26submit_fld_opt=.
43. ClinicalTrials.gov. Palbociclib (PD-0332991) combined with fulvestrant in hormone receptor+ HER2-negative metastatic breast cancer after endocrine failure (PALOMA-3). [accessed 14.10.14]. http://www.clinicaltrials.gov/ct2/show/NCT01942135?term=palbociclib+breast+cancer%26rank=1%26submit_fld_opt=.
44. ClinicalTrials.gov. Study of efficacy and safety of LEE011 in postmenopausal women with advanced breast cancer (MONALEESA-2). [accessed 14.10.14]. http://www.clinicaltrials.gov/ct2/show/NCT01958021?term=MONALEESA-2%26rank=1.
45. ClinicalTrials.gov. A study of LY2835219 combined with fulvestrant in women with hormone receptor positive HER2 negative breast cancer (MONARCH 2). [accessed 14.10.14]. http://www.clinicaltrials.gov/ct2/show/NCT02107703?term=MONARCH+2%26rank=1.
46. ClinicalTrials.gov. Exemestane with or without entinostat in treating postmenopausal patients with recurrent hormone receptor-positive breast cancer that is locally advanced or metastatic. [accessed 14.10.14]. http://www.clinicaltrials.gov/ct2/show/NCT02115282?term=Entinostat+breast+cancer%26rank=4.
47. Osborne C.K., Neven P., Dirix L.Y., Mackey J.R., Robert J., Underhill C., et al. Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study. Clin Cancer Res 2011, 17(5):1147-1159. 10.1158/1078-0432.CCR-10-1869.
48. Cristofanilli M., Valero V., Mangalik A., Royce M., Rabinowitz I., Arena F.P., et al. Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer. Clin Cancer Res 2010, 16(6):1904-1914. 10.1158/1078-0432.CCR-09-2282.
49. Johnston S.R.D., Basik M., Hegg R., Lausoontornsiri W., Grzeda L., Clemons M., et al. Phase II randomized study of the EGFR, HER2, HER3 signaling inhibitor AZD8931 in combination with anastrozole (A) in women with endocrine therapy (ET) naive advanced breast cancer (MINT). J Clin Oncol 2013, 31(Suppl.). [abstract 531].
50. Higgins M.J., Doyle C., Paepke S., Azaro A., Martin M., Semiglazov V., et al. A randomized, double-blind phase II trial of exemestane plus MM-121 (a monoclonal antibody targeting ErbB3) or placebo in postmenopausal women with locally advanced or metastatic ER+/PR+, HER2-negative breast cancer. J Clin Oncol 2014, 32(Suppl.). [abstract 587].
51. Robertson J.F., Ferrero J.M., Bourgeois H., Kennecke H., de Boer R.H., Jacot W., et al. Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial. Lancet Oncol 2013, 14(3):228-235. 10.1016/S1470-2045(13)70026-3.
52. Ibrahim N.K., Yariz K.O., Bondarenko I., Manikhas A., Semiglazov V., Alyasova A., et al. Randomized phase II trial of letrozole plus anti-MUC1 antibody AS1402 in hormone receptor-positive locally advanced or metastatic breast cancer. Clin Cancer Res 2011, 17(21):6822-6830. 10.1158/1078-0432.CCR-11-1151.
53. Bachelot T., Bourgier C., Cropet C., Ray-Coquard I., Ferrero J.M., Freyer G., et al. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J Clin Oncol 2012, 30(22):2718-2724. 10.1200/JCO.2011.39.0708.
54. Finn R.S., Crown J.P., Lang I., Boer K., Bondarenko I.M., Kulyk S.O., et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol 2014, [epub ahead of print]. 10.1016/S1470-2045(14)71159-3.
55. Finn R.S., Crown J.P., Lang I., Boer K., Bondarenko I.M., Kulyk S.O., et al. Results of a randomized phase 2 study of PD 0332991, a cyclin-dependent kinase (CDK) 4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER+, HER2-advanced breast cancer (TRIO-18). Cancer Res 2012, 72(24). [abstract S1-6].
56. Yardley D.A., Ismail-Khan R.R., Melichar B., Lichinitser M., Munster P.N., Klein P.M., et al. Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor. J Clin Oncol 2013, 31(17):2128-2135. 10.1200/JCO.2012.43.7251.
57. Paul D., Vukelja S.J., Holmes F.A., Blum J.L., McIntyre K.J., Kumar A.R., et al. Letrozole plus dasatinib improves progression-free survival (PFS) in hormone receptor-positive, HER2-negative postmenopausal metastatic breast cancer (MBC) patients receiving first-line aromatase inhibitor (AI) therapy. Presented at: 2013 San Antonio Breast Cancer Symposium; December 10-14, San Antonio, TX 2013, [abstract S3-07].
58. Finn R.S., Dering J., Conklin D., Kalous O., Cohen D.J., Desai A.J., et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res 2009, 11(5):R77. 10.1186/bcr2419.
59. Dean J.L., McClendon A.K., Hickey T.E., Butler L.M., Tilley W.D., Witkiewicz A.K., et al. Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors. Cell Cycle 2012, 11(14):2756-2761. 10.4161/cc.21195.
60. Vallabhaneni S., Nair B.C., Cortez V., Challa R., Chakravarty D., Tekmal R.R., et al. Significance of ER-Src axis in hormonal therapy resistance. Breast Cancer Res Treat 2011, 130(2):377-385. 10.1007/s10549-010-1312-2.
61. Wright G.L., Blum J., Krekow L.K., McIntyre K.J., Wilks S.T., Rabe A.C., et al. Randomized phase II trial of fulvestrant with or without dasatinib in postmenopausal patients with hormone receptor-positive metastatic breast cancer previously treated with an aromatase inhibitor. Cancer Res 2011, 71(24 Suppl. 3). [abstract PD01-01].
62. Llombart A., Ravaioli A., Strauss L., Sy O., Abrahao F., Geese W.J., et al. Randomized phase II study of dasatinib vs placebo in addition to exemestane in advanced ER/PR-positive breast cancer [BMS CA180-261 study]. Cancer Res 2011, 71(24 Suppl. 3). [abstract PD01-02].
63. Sabnis G.J., Goloubeva O., Chumsri S., Nguyen N., Sukumar S., Brodie A.M. Functional activation of the estrogen receptor-alpha and aromatase by the HDAC inhibitor entinostat sensitizes ER-negative tumors to letrozole. Cancer Res 2011, 71(5):1893-1903. 10.1158/0008-5472.CAN-10-2458.
64. Broglio K.R., Berry D.A. Detecting an overall survival benefit that is derived from progression-free survival. J Natl Cancer Inst 2009, 101(23):1642-1649. 10.1093/jnci/djp369.